<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>356</serviceExecutionTime><Drug id="95116"><DrugName>MEDI-6469 + tremelimumab (solid tumor), MedImmune/AstraZeneca</DrugName><DrugSynonyms><Name><Value>MEDI-6496 + tremelimumab (solid tumor), MedImmune</Value></Name><Name><Value>MEDI-6469 + tremelimumab (solid tumor), MedImmune/AstraZeneca</Value></Name><Name><Value>CTLA-4 checkpoint inhibitor + OX40 costimulator (solid tumor), MedImmune</Value></Name></DrugSynonyms><CompanyOriginator id="18008">MedImmune LLC</CompanyOriginator><CompaniesSecondary><Company id="18008">MedImmune LLC</Company></CompaniesSecondary><CrossReferences><SourceEntity id="18008" type="Company"><TargetEntity id="4295907119" type="organizationId">Medimmune LLC</TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="5443" type="Action"><TargetEntity id="4914" type="Mechanism">Tumor Necrosis Factor Receptor Superfamily Member 4 (OX40, CD134) Agonists</TargetEntity></SourceEntity><SourceEntity id="5482" type="Action"><TargetEntity id="5219" type="Mechanism">CTLA-4 Inhibitors</TargetEntity><TargetEntity id="1591" type="Mechanism">Anti-CD152 (CTLA-4)</TargetEntity></SourceEntity><SourceEntity id="PTGT-00415" type="ciTarget"><TargetEntity id="212728885972933" type="siTarget">Tumor necrosis factor receptor superfamily member 4</TargetEntity><TargetEntity id="2341" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00423" type="ciTarget"><TargetEntity id="183199231714933" type="siTarget">Cytotoxic T-lymphocyte protein 4</TargetEntity><TargetEntity id="167" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="5482">Cytotoxic T-lymphocyte protein-4 inhibitor</Action><Action id="5443">OX-40 receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="393">Immunostimulant</Action><Action id="55685">Anticancer monoclonal antibody</Action><Action id="7761">T-lymphocyte stimulator</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="175">Drug combination</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="168">Monoclonal antibody human</Technology></Technologies><EphmraCodes><Ephmra><Code>L3</Code><Name>IMMUNOSTIMULATING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-03-28T04:22:21.000Z</LastModificationDate><ChangeDateLast>2018-01-05T00:00:00.000Z</ChangeDateLast><AddedDate>2015-05-14T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18008" linkType="Company"&gt;MedImmune&lt;/ulink&gt;, the biologics subsidiary of &lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt;, was developing  a combination of the humanized OX40 agonist mAb &lt;ulink linkID="71965" linkType="Drug"&gt;MEDI-6469&lt;/ulink&gt;	 and  the human anti-CTLA-4 mAb &lt;ulink linkID="45562" linkType="Drug"&gt;tremelimumab&lt;/ulink&gt; for the potential iv treatment of solid tumors [&lt;ulink linkID="1631825" linkType="Reference"&gt;1631825&lt;/ulink&gt;], [&lt;ulink linkID="1631551" linkType="Reference"&gt;1631551&lt;/ulink&gt;]. In December 2014, the combination was listed for the first time on AstraZeneca's pipeline, with phase I development for solid tumors stated to have commenced in Q4 2014 [&lt;ulink linkID="1631551" linkType="Reference"&gt;1631551&lt;/ulink&gt;], presumably as a result of the start of testing of the combination in an ongoing phase Ib/II trial evaluating MEDI-6469 alone and in combination with selected drugs, including tremelimumab [&lt;ulink linkID="1582364" linkType="Reference"&gt;1582364&lt;/ulink&gt;]; however, by November 2015, the drug had been discontinued due to strategic reasons [&lt;ulink linkID="1710133" linkType="Reference"&gt;1710133&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In August 2014, MedImmune initiated a non-randomized, open-label, phase Ib/II trial (&lt;ulink linkID="207041" linkType="Protocol"&gt;NCT02205333&lt;/ulink&gt;; D4981C00001) in the US of  MEDI-6469 alone and as part of various drug combinations, including MEDI-6469 plus tremelimumab in subjects with solid tumors. At that time, the trial was expected to complete in September 2017 [&lt;ulink linkID="1582364" linkType="Reference"&gt;1582364&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-11-05T00:00:00.000Z</StatusDate><Source id="1710133" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00415"><Name>OX-40 receptor</Name><SwissprotNumbers><Swissprot>P15725</Swissprot><Swissprot>P43489</Swissprot><Swissprot>P47741</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00423"><Name>Cytotoxic T-lymphocyte protein-4</Name><SwissprotNumbers><Swissprot>P09793</Swissprot><Swissprot>P16410</Swissprot><Swissprot>P42072</Swissprot><Swissprot>Q9MYX7</Swissprot><Swissprot>Q9XSI1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>